Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
jRCT2080223116Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denileukin diftitox in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Eisai Co., Ltd. Primary endpoint: Overall response rate (ORR) by independent review in full analysis set. Started Feb 2016; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on jRCT2080223116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223116.